Scipher Medicine Launches PrismTcell Response Signature for Abatacept
Scipher Medicine launched PrismTcell, a molecular treatment response signature for abatacept in rheumatoid arthritis.
Related stories
4-PAG to Acquire 51% Stake in Evergrande Property Services
M impact | EQUITY | Oct 30, 2026, 05:07 AM UTC
PAG to Acquire 51% of Evergrande Property Services
PAG will acquire a 51% stake in Evergrande Property Services.
M impact | EQUITY | Oct 30, 2026, 05:07 AM UTC
Proya Shares Hit Limit Down, Fall 8.4% in Morning Trade
China cosmetics maker Proya traded at its daily limit-down level of 48.86 yuan, its lowest since Feb. 4, 2020, before closing the morning session down 8.4%. Citi cut its price targ
M impact | EQUITY | Oct 30, 2026, 04:46 AM UTC
Amazon Shares Fall 6% After Disappointing Wall Street
Amazon shares fell 6%, according to the headline.
M impact | EQUITY | Oct 30, 2026, 04:33 AM UTC
Asian session market picture: S&P 500 -0.91%, Nasdaq 100 -1.92%; USD/JPY -0.2%, WTI +1.15%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.91 percent, Nasdaq futures is down 1.92 percent, Dow futures is down 0.2 percent and Russell futures is do
M impact | EQUITY | Oct 30, 2026, 04:30 AM UTC
Indian shares inch higher as IT stocks and earnings rebound offset oil pressure
The Nifty 50 added 0.24% to 22,987.40 and the Sensex rose as IT stocks and post-results gains offset pressure from higher crude prices.
M impact | EQUITY | Oct 30, 2026, 04:29 AM UTC